Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.

Breast Cancer Res · 2011 · PMC3326551 · PMID 22044691

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

of borderline significanceP ≤0.15not close (p > 0.1)

Interaction of borderline significance ( P ≤0.15) was observed for CK14, Angiogenin, and β-Catenin, with a trend towards docetaxel benefit for patients with a marker-positive tumor.

also in 1,681 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.